Skip to main content

Evans John M.'s Form 4 filing

Beam Therapeutics Inc.BEAM · filed Feb 2, 2026

Accession no.
0001193125-26-033600
Filed
Feb 2, 2026
Trade date
Jan 29-31, 2026
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 7 non-derivative transactions and 4 derivative transactions. Open-market sales total $1.44M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Evans John M.CIK 0001786304Director, Officer (CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 29, 2026Common StockMOption exerciseAcquired+19,336$0.67+$12,955.121,006,003Direct
Jan 29, 2026Common StockMOption exerciseAcquired+5,664$0.67+$3,794.881,011,667Direct
Jan 29, 2026Common StockSSaleDisposed−16,333$29.19F2−$476,760.27995,334Direct
Jan 29, 2026Common StockSSaleDisposed−8,667$29.74F3−$257,756.58986,667Direct
Jan 30, 2026Common StockMOption exerciseAcquired+25,000$0.67+$16,7501,011,667Direct
Jan 30, 2026Common StockSSaleDisposed−22,094$28.27F4−$624,597.38989,573Direct
Jan 30, 2026Common StockSSaleDisposed−2,906$29.00−$84,274986,667Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 29, 2026Common StockMOption exerciseDisposed−19,336$0.00$00Direct
Jan 29, 2026Common StockMOption exerciseDisposed−5,664$0.00$093,672Direct
Jan 30, 2026Common StockMOption exerciseDisposed−25,000$0.00$068,672Direct
Jan 31, 2026Common StockAGrant or awardAcquired+180,000$0.00$0180,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $28.65 to $29.64 inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Referenced by the price of 1 transaction in Table I.

F3

The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $29.66 to $29.92 inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Referenced by the price of 1 transaction in Table I.

F4

The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $27.87 to $28.82 inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)